Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in three upcoming investor conferences in New York, NY.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in three upcoming investor conferences in New York, NY. The events include:
1. Morgan Stanley 22nd Annual Global Healthcare Conference - 1x1 Investor Meetings on Friday, September 6, 2024
2. Baird 2024 Global Healthcare Conference - Fireside Chat on Wednesday, September 11, 2024, at 7:55am ET
3. Chardan's 8th Annual Genetic Medicines Conference - Fireside Chat on Monday, September 30, 2024, at 4:30pm ET
These conferences provide Vor Bio with opportunities to engage with investors and showcase their latest developments in cell and genome engineering.
Details
News Market Reaction – VOR
The recorded move for VOR in the trading session of this news was -3.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
1x1 Investor Meetings: Friday, September 6, 2024
Location: New York, NY
Baird 2024 Global Healthcare Conference
Fireside Chat: Wednesday, September 11, 2024, at 7:55am ET
Location: New York, NY
Chardan’s 8th Annual Genetic Medicines Conference
Fireside Chat: Monday, September 30, 2024, at 4:30pm ET
Location: New York, NY
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.